Program management in medical device development is the coordinated planning and control of a device program across its full lifecycle, aligning engineering, quality, regulatory, clinical, and supply-chain workstreams against design controls, risk management, and phase-gate reviews so a compliant product reaches market on schedule.
What is program management in medical device development?
Program management sits one level above project management. A project delivers a single defined output, such as a completed verification test campaign. A program coordinates several related projects and functions toward a strategic outcome: a market-ready, regulatory-cleared device. The program manager owns scope, schedule, budget, and risk across the whole effort, and holds the gate reviews where the program either advances or stops.
In a regulated setting, that coordination is not optional overhead. Design controls under ISO 13485:2016 clause 7.3 and the FDA Quality Management System Regulation (QMSR, 21 CFR Part 820, effective February 2, 2026) require documented planning, defined responsibilities, and design reviews at planned stages. Program management is where those requirements get scheduled, resourced, and tracked.
Why program management matters in medical device development
A device program carries risks that a typical commercial product does not. A missed design input can surface as a field failure years later. A gap in the design history file can stall a 510(k) or delay CE marking under EU MDR 2017/745. Weak coordination between R&D and manufacturing shows up as a failed process validation during design transfer.
Good program management contains these risks early, when changes are cheap. It keeps risk management (ISO 14971:2019) tied to design decisions rather than bolted on before submission. It gives leadership honest visibility into whether a launch date is real. And it protects audit readiness: when a notified body or FDA investigator asks for evidence that reviews happened at the right points, that evidence exists because the program was run to a plan.
How program management works
Most medical device programs run on a phase-gate (stage-gate) model. Work is divided into phases, and each gate is a formal decision point with defined entry and exit criteria. A typical structure:
- Concept and feasibility. Define user needs, intended use, and preliminary risk. Confirm the idea is technically and commercially viable.
- Planning. Establish the design and development plan, resource the workstreams, and set the regulatory strategy and device classification.
- Design and development. Translate user needs into design inputs, then into design outputs. Run design reviews and keep the risk file current.
- Verification and validation. Confirm outputs meet inputs (verification) and that the device meets user needs (validation), including electrical safety and EMC testing to the IEC 60601 family where applicable.
- Design transfer. Move the validated design into manufacturing with process validation (IQ/OQ/PQ) and a controlled bill of materials.
- Launch and post-market. Release to market and hand off to post-market surveillance and sustaining engineering.
Around this backbone, the program manager runs change control, so a design change triggers the right re-verification instead of quietly invalidating earlier work. Software workstreams follow IEC 62304 for lifecycle activities. Cross-functional standups, a living risk register, and a schedule tied to gate criteria keep the phases connected rather than siloed.
Common challenges and best practices
The most common failure is treating gates as calendar events rather than evidence checks. A gate that passes without meeting exit criteria just moves the problem downstream, where it costs more. Hold gates on readiness, not on the date.
A second problem is disconnected documentation. When the design history file, risk file, and schedule live in separate places maintained by separate people, they drift. Teams that keep traceability from user needs through verification in one controlled system spend far less time reconstructing evidence before an audit.
Scope creep is a third. Late requirement changes ripple through design inputs, risk analysis, and validation. Strong change governance does not block change; it makes the full cost of each change visible before it is approved. Bring quality and regulatory into the program from day one. Programs that treat QA/RA as a final checkpoint routinely discover, too late, that a design decision closed off a viable regulatory pathway.
How SJML helps with program management
Syrma Johari MedTech (SJML) runs device programs end to end, from concept and feasibility through architecture, design, verification, and design transfer. Phase-gate program management with structured change control is built into how its engineering teams work, with risk management (ISO 14971) and usability engineering (IEC 62366) integrated rather than added late. In-house labs support electrical safety, IEC 60601, EMC, reliability, and environmental testing, so verification does not wait on external queues. QARA support runs alongside development, keeping regulatory strategy aligned with design decisions across Class I, II, and III devices.
Talk to SJML’s engineering team →
Frequently asked questions
A project delivers one defined output, such as a verification study or a design transfer. A program coordinates several related projects and functions toward a strategic goal, usually a cleared, market-ready device. Program management owns cross-functional scope, schedule, budget, and risk, and runs the gate reviews. Project management executes the individual pieces inside that larger structure.
A phase-gate (or stage-gate) process splits development into phases separated by formal decision points. Each gate has defined entry and exit criteria that must be met before the program advances. It gives leadership structured go, no-go, or hold decisions and creates the documented design reviews that ISO 13485 and the FDA QMSR expect at planned stages of design and development.
No single standard is titled program management, but several shape it. ISO 13485:2016 clause 7.3 sets design and development planning and review requirements. The FDA QMSR (21 CFR Part 820) applies in the U.S., and the EU MDR 2017/745 in Europe. ISO 14971:2019 governs risk management, and IEC 62304 covers software lifecycle activities within the program.
Regulatory planning belongs in the earliest phases, during concept and planning, not before submission. Device classification and the intended regulatory pathway shape design inputs, testing requirements, and documentation. Starting late is a frequent cause of rework because a design already frozen may not support the evidence a chosen pathway requires.
Related terms
- Design Controls
- Design and Development Planning
- Design Transfer
- Phase-Gate Process
- Design History File (DHF)
